Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $74 | $73 | $73 | $66 |
| - Cash | $71 | $59 | $71 | $137 |
| + Debt | $10 | $11 | $12 | $12 |
| Enterprise Value | $13 | $26 | $14 | -$58 |
| Revenue | $0 | $0 | $0 | $7 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $3 |
| % Margin | – | – | – | 50% |
| EBITDA | -$20 | -$26 | -$26 | -$63 |
| % Margin | – | – | – | -914.9% |
| Net Income | -$21 | -$22 | -$23 | -$48 |
| % Margin | – | – | – | -708.4% |
| EPS Diluted | -0.99 | -1.05 | -1.08 | 2.41 |
| % Growth | 5.7% | 2.8% | -144.8% | – |
| Operating Cash Flow | -$20 | -$19 | -$21 | -$49 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$20 | -$20 | -$22 | -$50 |